Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination vaccine** composed of diphtheria toxoid, tetanus toxoid, and inactivated poliovirus antigens. It is designed to induce an immune response and confer protection against **diphtheria**, **tetanus**, and **poliomyelitis**. The mechanism of action relies on stimulating adaptive immunity, causing the body to produce specific antibodies and cell-mediated responses against the bacterial toxins (diphtheria, tetanus) and the poliovirus. It is commonly administered to children as part of routine immunization schedules and is used worldwide for booster immunization, especially before school entry. The vaccine does not treat active infections; it is purely prophylactic. Approved brand formulations include Kinrix (GlaxoSmithKline), Quadracel (Sanofi), Adacel-Polio (Sanofi), and Boostrix-Polio (GlaxoSmithKline)[1][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphtheria vaccine + tetanus vaccine + inactivated poliomyelitis vaccine.